Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Will Accept Behind-The-Counter NDAs While Mulling “Continuum” Class

This article was originally published in The Tan Sheet

Executive Summary

FDA is open to behind-the-counter switch applications in which companies propose innovative methods to solve access or selection issues, according to Office of Nonprescription Products staff

You may also be interested in...



OTC Switch Offers Firms Opportunities To Diversify Earnings – Morgan Stanley

Rx-to-OTC switches offer drug firms a "meaningful opportunity" to diversify their earnings, which is gaining importance in an "increasingly challenging pharmaceutical landscape" Morgan Stanley market analysts say

OTC Switch Offers Firms Opportunities To Diversify Earnings – Morgan Stanley

Rx-to-OTC switches offer drug firms a "meaningful opportunity" to diversify their earnings, which is gaining importance in an "increasingly challenging pharmaceutical landscape" Morgan Stanley market analysts say

OTC Switch Offers Firms Opportunities To Diversify Earnings – Morgan Stanley

Rx-to-OTC switches offer drug firms a "meaningful opportunity" to diversify their earnings, which is gaining importance in an "increasingly challenging pharmaceutical landscape" Morgan Stanley market analysts say

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS100520

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel